Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Resubmission Letter - CINRYZE

Our STN: BL 125267/0

Lev Pharmaceuticals, Inc.
Attention: Mr. Jason Bablak
675 Third Avenue
Suite 2200
New York , NY 10017

Dear Mr. Bablak :

We have received your 14 April 2008 resubmission to your biologics license application for C1 Esterase Inhibitor (Human) on14 April 2008.

The resubmission contains additional CMC, clinical, and statistical information that you submitted in response to our 30 January 2008 complete response letter.

We consider this a complete, class 2 response to our action letter. Therefore, the goal date is 14 October 2008.

If you have any questions, please contact me at (301) 827-6174.

Sincerely yours,


Nannette Cagungun
Regulatory Project Manager
Division of Blood Applications
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Page Last Updated: 03/03/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English